Home  >  News
Msc_Apr23 Advertisement
you can get e-magazine links on WhatsApp. Click here
  ABK Biomedical gets US FDA IDE approval for multi-centre pivotal study of Eye90 microspheres in hepatocellular carcinoma,   June 01, 2023
  US FDA grants Fast Track Designation to Inhibrx’s INBRX-101 to treat alpha-1 antitrypsin deficiency,   June 01, 2023
  Lupin’s subsidiary, Novel Labs gets US FDA approval for diazepam rectal gel,   June 01, 2023
  Amgen to present new research on Otezla in psoriatic arthritis at EULAR 2023,   June 01, 2023
  US FDA proposes new, easy-to-read medication guide for patients, Patient Medication Information,   June 01, 2023
  AbbVie announces phase 2 study of upadacitinib alone or as a combo therapy meets primary and key secondary endpoints in patients with SLE,   June 01, 2023
  Nestlé Health Science collaborates with IAPEN to strengthen awareness on gut health management,   June 01, 2023
  Precision oncology offers future prospects for biliary tract cancer,   June 01, 2023
  Venus Remedies gets Saudi Arabian marketing approval for chemotherapy drug, docetaxel,   June 01, 2023
  Dental care startup Smiles.ai rebrands as Dezy,   June 01, 2023
  Pfizer reports positive marstacimab results from pivotal phase 3 haemophilia A and B trial,   June 01, 2023
  Tata Memorial Centre launches music video campaign to steer youth away from tobacco use,   June 01, 2023
  Evercare Group's quality conference facilitates collaboration and quality improvement in healthcare,   June 01, 2023
  ImmunoACT raises Rs. 80 crore in Series B funding from Laurus Labs,   June 01, 2023
  Global regulators agree on way forward to adapt Covid-19 vaccines to emerging variants,   June 01, 2023
  Lupin gets US FDA approval for generic Ocaliva tablets,   June 01, 2023
  Torrent Pharma posts net profit of Rs. 287 crore in Q4, total dividend of 440%,   June 01, 2023
  US FDA accepts for priority review of Bristol Myers Squibb’s NDA for repotrectinib to treat locally advanced or metastatic ROS1-positive NSCLC,   June 01, 2023
  Sanofi announces positive phase 2 data of novel investigational anti-CD40L antibody frexalimab to treat relapsing multiple sclerosis,   June 01, 2023
  Genprex gets Safety Review Committee nod to advance to phase 2 expansion portion of Acclaim-1 trial of Reqorsa in combo with Tagrisso in advanced NSCLC,   May 31, 2023

Copyright © 2016 Saffron Media Pvt. Ltd |